BioCentury
ARTICLE | Company News

PDL BioPharma, UCB autoimmune news

February 14, 2011 8:00 AM UTC

The companies settled all legal disputes, including proceedings related to UCB's Cimzia certolizumab pegol and PDL's Queen et al. patents, which cover humanized antibodies. Under the settlement, PDL will waive its right to sue UCB for royalties on Cimzia and one undisclosed UCB antibody program under the patents in exchange for a payment of $10 million. Cimzia is approved in the EU and U.S. for rheumatoid arthritis (RA) and in the U.S. for Crohn's disease. The pegylated humanized antibody fragment against tumor necrosis factor (TNF) alpha is partnered with Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) in Japan. Cimzia had €138 million ($188.1 million) in sales for the first nine months of 2010. ...